1 / 22

ACRIN Breast Committee

A study on utilizing contrast-enhanced MRI to assess response in neoadjuvant breast cancer treatment, providing early prediction and outcome insights. The research evaluates imaging markers and disease-free survival prediction.

johnolin
Download Presentation

ACRIN Breast Committee

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ACRIN Breast Committee Fall Meeting 2010 6657 CONTRAST-ENHANCED BREAST MRI FOR EVALUATION OF PATIENTS UNDERGOING NEOADJUVANT TREATMENT FOR LOCALLY ADVANCED BREAST CANCER Nola Hylton, PhD Jeffrey Blume, PhD 6657 Trial Team ACRIN Breast Committee

  2. ACRIN 6657 (Original Trial) • ACRIN 6657 is evaluating contrast-enhanced MRI for assessing response to neoadjuvant treatment • ACRIN 6657 is the imaging component of the larger I-SPY neoadjuvant breast cancer treatment trial (CALGB 150007/150012, ACRIN 6657, CBIIT, InterSPORE)

  3. I-SPY-1 SCHEMANeoadjuvant Chemotherapy for Breast Cancer Anthracycline Taxane ClinicalStudy Surgery MRI MRI MRI MRI Core biopsy Core biopsy • Patients recruited and enrolled through CALGB 150007 (single consent) • Eligibility: women with locally-advanced breast cancer (≥3 cm tumors) receiving neoadjuvant chemotherapy • MRI’s and core biopsies at multiple time-points during treatment • Original target accrual: 244 patients

  4. Progression of imaging studies 2002 ACRIN 6657 Original Contrast enhanced breast MRI for measuring response and predicting 3-yr RFS I-SPY 1 Standard AC-T 2007 ACRIN 6657 Extension Choline (tCho) measured by MRS for early prediction of response ACRIN 6693 (I-SPY 2) Multi-parametric MR imaging markers (ADC, SER, tCho) for measuring response to targeted agents I-SPY 2 T + novel agent 2010

  5. ACRIN 6657 Imaging Questions SURGERY Taxane Anthracycline ClinicalStudy 3-YR DFS MRI MRI MRI MRI Core biopsy Core biopsy Can MRI predict disease-free survival following treatment? Primary ImagingQuestion:

  6. ACRIN 6657 Imaging Questions SURGERY Taxane Anthracycline ClinicalStudy MRI MRI MRI MRI Core biopsy Core biopsy INTERMEDIATE ENDPOINTS Clinical Response, pCR, RCB SecondaryImagingQuestion: Can MRI provide early prediction of response to treatment?

  7. ACRIN 6657 Imaging Protocol • Eligibility: I-SPY enrollment; women with ≥ 3 cm invasive breast cancer receiving anthracycline-cyclophosphamide (AC) chemotherapy followed by a taxane (T) • Four MRI exams: baseline, after 1 cycle AC, between AC and T, following T before surgery • MRI protocol: • unilateral, sagittal, scan of symptomatic breast • 2D, fat-suppressed,T2-weighted fast spin echo sequence • 3-time point contrast-enhanced 3D, fat-suppressed, T1-weighted series

  8. Status – 6657 Original • 237 patients enrolled May 2002 - March 2006 at 9 institutions • 3-year recurrence-free survival (RFS) follow-up completed in August 2009 • Analysis Set = 216 (7 ineligible; 14 with incomplete imaging) • Preliminary analysis of secondary question: • Correlation of imaging and residual disease size after surgery • Early prediction of response (after 1 cycle of AC)

  9. MRI Measurements • Tumor Longest Diameter • Morphologic Pattern • Tumor Volume • Peak Signal Enhancement Ratio (SER) Radiologist assessment By computer analysis

  10. Volume and Peak SER • Tumor volume computed based on enhancement thresholds • Sum of all pixels with percent enhancement PE > 70%* and SER > 0.9 • Peak SER measured as highest mean value of 8 connected pixels measured over the entire tumor

  11. Summary of Results – RSNA 2008 • MRI estimates residual disease size better than clinical exam or mammography • Of MRI measurements, volume performs better than longest diameter or peak SER • In univariate and multivariate models, MRI volume change after 1 cycle of chemotherapy was the only early measurement that predicted clinical response and pCR (2008 analysis)

  12. Results from I-SPY 1 Response to Therapy is Associated with Better Relapse Free Survival

  13. AXILLARY NODAL BURDEN + Residual Cancer Burden PRIMARY TUMOR BURDEN RCB = 1.4 x [fcell x (d1 d2)] 0.17 + [dmet x (1 - (1 -  ) LN ) / ] 0.17 PRIMARY TUMOR BURDEN Area (cm x cm) Area (cm x cm) % CANCER CELLULARITY % CANCER CELLULARITY Symmans et al. J Clin Oncol. 2007 Oct 1;25(28):4414-22. Number of positive LNs Diameter of largest metastasis (mm)

  14. Residual Cancer Burden • Integrates several pathologic features • Lymph node status • Extent of tumor bed • Tumor size • Tumor cellularity • Output is continuous or 4 discrete categories • RCB 0 pCR, no invasive tumor • RCB I scattered residual disease • RCB II moderate tumor burden • RCB III significant tumor burden Symmans et al JCO 2007

  15. Results from I-SPY 1 Survival by Residual Cancer Burden (RCB) Index

  16. Results from I-SPY 1 pCR is a Better Predictor by Subtype

  17. Summary of Results – 2010 Prediction of Pathologic Response

  18. Summary of Results – 2010 Prediction of RCB and ‘in-breast’ component

  19. Summary of Results – 2010 • Analysis of primary question being finalized • Prediction of 3-year recurrence-free survival (RFS) • Primary question focused on ability of MRI to stratify survival among clinical partial/minimal responders • Results from preliminary analysis are promising: • MRI predicts better than mammography or clinical exam • MRI can further stratify partial/minimal responders

  20. Publications • Primary and secondary aims: • 1st paper submission (early prediction of response) November 2010 • 2nd paper submission (survival prediction) February 2011 • Additional publications planned: • Residual disease correlation with pathology (MMG, MRI) • Morphologic pattern association with response and surgical outcome • Conditional probability of MR response to taxane based on response to AC

  21. Additional studies planned • Comparison of biopsy yield for MRI, US, physical exam • Evaluation of MRI prediction among breast cancer subtypes by molecular and genomic signatures • Testing of alternative quantitative metrics

  22. 6657/I-SPY Trial Team • ACRIN 6657 Trial Team • N. Hylton, B. Joe, M. Watkins, S. Suzuki, D. Newitt, E. Proctor, UCSF; J. Blume, H. Marques, B. Herman, C. Gatsonis, B. Dunning, ACRIN DMC; M. Rosen, M. Schnall, U Penn; E. Pisano, UNC, E. Morris, MSKCC; W. Bernreuter, UAB; S. Polin, Georgetown; C. Lehman, S. Partridge, U Wash; P. Weatherall, UTSW; G. Newstead, U Chicago; P. Bolan, U Minnesota; B. LeStage, N. Sauers, ACRIN Advocates • I-SPY Trial Network • L. Esserman, J. Gray, L Vantveer, UCSF; A. DeMichelle, U Penn; L Carey, C. Perou, UNC, L. Montgomery, C. Hudis, MSKCC; H. Krontiras, UAB; M. Liu, Georgetown; J. Gralow, U Wash; D. Tripathy, UTSW; F Olopade, U Chicago; D. Yee, U Minnesota; S. Madhavan, K. Buetow, E. Petricoin NCICB

More Related